Biogen Inc. - Common Stock · Transaction Sep 24, 2026 · Filed Oct 7, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · BIIB
+1.72% · +$3.93 · Vol Not reported
After hours · updated 16:00:00 ET
Biogen Inc
Biotechnology
$232.83
Follow $BIIB
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $BIIB by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredWed Oct 14 · session closed · Markets closed · resumes Thu 9:30 ET · BIIB
MethodologyBIIB
Biogen Inc
Wed Oct 14 · session closed · Markets closed · resumes Thu 9:30 ET
Highest qualified
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
80/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Wed Oct 14 · session closed · Markets closed · resumes Thu 9:30 ET
AI Analysis
SovereignWhy is BIIB moving today?
Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Biogen Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
1991
Employees
8K
Country
US
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$228.99
Day high
$234.20
Day low
$228.00
Previous close
$228.90
52W high
$234.20
-0.58% from high
52W low
$142.26
99% of range
Market cap
$33.8B
P/E
40.53×
EPS
$5.65
Beta
0.19
Shares out
147.8M
Avg volume
1.1M
VWAP
$228.90
Last session
Price history computed in-house
1W
+4.81%
1M
+7.12%
3M
+11.44%
1Y
+60.23%
YTD
+32.30%
SMA 50 $218.12 · above
SMA 200 $196.98 · above
52W position 99%
BIIB overview
Related filings and maps
Public disclosures
Congress activity in BIIB
25 filers · 43 buys · 46 sells (2 labeled S (partial)) · Dec 20, 2013 to Sep 24, 2026 · House 76 / Senate 13
All available history · Latest 5 of 89 lines · Read Oct 14, 2026, 11:01 PM UTC
Official filing ↗
Biogen Inc. - Common Stock · Transaction Jun 5, 2026 · Filed Jul 2, 2026 · $1,001 to $15,000
Biogen Inc. - Common Stock · Transaction Jun 2, 2026 · Filed Jul 7, 2026 · $15,001 to $50,000
Biogen Inc. - Common Stock · Transaction May 12, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
Biogen Inc. - Common Stock · Transaction Jan 30, 2026 · Filed Feb 13, 2026 · $1,001 to $15,000
Federal contracts
BIIB contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BIIB in this window.
Lobbying spend
BIIB lobbying filings, year to date.
Registered lobbying filings matched to Biogen Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BIIB in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for BIIB.